All In MedTech

Device Trial Radar · NCT05324514

Microscopic Skin Tissue Column Grafting Technique Using the Autologous Regeneration of Tissue System

Full-Thickness Microscopic Skin Tissue Column Grafting Technique Using the ART (Autologous Regeneration Tissue) System: An Interventional Clinical Trial

Last checked: Nov 20, 2026Latest source record: Aug 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 1, 2022

Primary completion

Oct 2024

Study completion Dec 2024

Sponsor

Lead sponsor
The Metis FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 12, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates Microscopic Skin Tissue Column (MSTC) grafting technique using the Autologous Regeneration Tissue (ART) System in the treatment of skin loss. Each participant will have three study treated areas, the three treatments include: 1. traditional grafting, 2. high density MSTC, 3. low density MSTC.

Conditions

  • Wound of Skin
  • Burns

Interventions

  • Split-thickness skin graftingProcedure

    Harvesting for split-thickness skin grafting will be performed at the specified donor site using a pneumatically powered dermatome with a setting of 10 /1000th inch and meshed 2:1.

  • High density microscopic skin tissue column graftingDevice

    MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at high density (300-360 columns/50cm2).

  • Low density microscopic skin tissue column graftingDevice

    MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at low density (150-180 columns/50cm2).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of healingTime frame: Day 7
  2. Rate of epithelializationTime frame: Day 7
  3. Rate of healingTime frame: Day 14

1 more outcomes with a free account

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.